Menu Search
Equities

Imricor Medical Systems Inc

IMR:ASX

Imricor Medical Systems Inc

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.825
  • Today's Change0.015 / 1.85%
  • Shares traded117.10k
  • 1 Year change+41.99%
  • Beta0.8508
Data delayed at least 20 minutes, as of Nov 18 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Imricor Medical Systems Inc's revenues fell -24.56% from 816.01k to 615.57k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 17.36m to a larger loss of 22.63m.
Gross margin-110.81%
Net profit margin-2,458.30%
Operating margin-1,916.14%
Return on assets-255.91%
Return on equity--
Return on investment-387.91%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Imricor Medical Systems Inc fell by 4.86m. Cash Flow from Financing totalled 8.21m or 1,334.32% of revenues. In addition the company used 12.98m for operations while cash used for investing totalled 82.78k.
Cash flow per share-0.1719
Price/Cash flow per share--
Book value per share-0.0492
Tangible book value per share-0.0492
More ▼

Balance sheet in USDView more

Imricor Medical Systems Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio1.46
Quick ratio0.799
Total debt/total equity--
Total debt/total capital4.73
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.